Health Canada Approves the First and Only Anti-BCMA CAR T cell Therapy for Multiple Myeloma
Bristol Myers Squibb Canada (BMS) today announced Health Canada has granted conditional approval (NOC/c)...
Read moreBristol Myers Squibb Canada (BMS) today announced Health Canada has granted conditional approval (NOC/c)...
Read moreA summary safety review (SSR) regarding Pomalyst (pomalidomide) and Thalomid (thalidomide) and the poten...
Read moreThe Canadian Cancer Trials Group (CCTG) and Queen’s researcher Annette Hay (Medicine) and Jonathan Bramso...
Read moreThis year, for the first time, the publication of the annual Cancer System Quality Index by Cancer Care O...
Read more(Toronto, Ont.) January 27, 2021 ¬– FORUS Therapeutics launches today, bringing a new pharmaceutical comp...
Read moreFarmers have a higher incidence of multiple myeloma, and there is suggestive evidence of an elevated prev...
Read moreJoin our community and sign up for our newsletter.